Management ChangeJun 4, 2026, 07:02 AM
BeyondSpring Appoints Min Qiu as CEO, Na Li as CFO; Dr. Majeti as Vice Chairman
AI Summary
BeyondSpring Inc. announced a leadership transition effective July 1, 2026, appointing Min Qiu as Chief Executive Officer and Na Li as Chief Financial Officer. Dr. Jiangwen (Jen) Majeti was named Vice Chairman. Founder Dr. Lan Huang will remain Chairman of BeyondSpring while dedicating her executive focus to SEED Therapeutics. These changes aim to accelerate the DUBLIN-4 confirmatory Phase 3 program for Plinabulin and expand its global partner and investor base.
Key Highlights
- Min Qiu appointed Chief Executive Officer, effective July 1, 2026.
- Na Li appointed Chief Financial Officer, effective July 1, 2026.
- Dr. Jiangwen (Jen) Majeti appointed Vice Chairman, effective July 1, 2026.
- Dr. Lan Huang remains Chairman of BeyondSpring, focusing executive time on SEED Therapeutics.
- Plinabulin's U.S. composition-of-matter protection extends through 2036, potentially to 2041.
- DUBLIN-4 is a 442-patient confirmatory Phase 3 trial for Plinabulin.
- DUBLIN-3 study showed Plinabulin reduced grade 4 neutropenia from 33% to 5%.
Price Impact
More from BYSI